Imperfect Cognitions

This post is by Elly Vintiadis who recently guest-edited a special issue of Philosophical Psychology on psychedelic-assisted therapy and wrote a free access introduction to the special issue entitled The Promises and Perils of the Psychedlic Turn in Psychiatry . Elly Vintiadis Psychedelic substances have been part of human culture for centuries, used in ritual, healing and spiritual contexts to induce altered states of consciousness that could bring insight and change. In recent years, they have re-emerged in psychiatry in psychedelic-assisted therapy (PAT), a therapeutic framework in which substances such as psilocybin, LSD, MDMA, ketamine, or ibogaine are administered in controlled conditions, accompanied by preparation, supervision and integration. Research into psychedelic therapies flourished in the mid-20th century but came to a halt in the early 1970s, driven by shifting social attitudes and the onset of the War on Drugs. With their classification as Schedule I substances under ...

This post is by Chris Letheby . In recent decades there has been a growing interdisciplinary attempt to understand self-awareness by integrating empirical results from neuroscience and psychiatry with philosophical theorizing. This is exemplified by the enterprise known as ‘philosophical psychopathology’, in which observations about unusual cognitive conditions are used to infer conclusions about the functioning of the healthy mind. But this line of research has been somewhat limited by the fact that pathological alterations to self-awareness are unpredictable and can only be studied retrospectively—until now. The recent resurgence of scientific interest in ‘classic’, serotonergic psychedelic drugs such as LSD and psilocybin has changed all this. Using more rigorous methods than some of their forebears, psychiatrists have shown that psychedelics can, after all, be given safely in clinical contexts, and may even cause lasting psychological benefits. Small studies have shown ...